The answer is that they aren’t accessible to most immunotherapies because of where they are — inside the cancer cells. And that is where T cell receptor therapy has a huge advantage over other types ...

T-cell receptors (TCRs) recognize small protein fragments (peptides) that are displayed on the surface of antigen-presenting cells. Each T cell expresses a unique TCR that is generated by randomly ...

According to new research, T cells have a nuclear receptor doing something very odd—but very important—to help them fight pathogens and destroy cancer cells. This receptor, called retinoic ...

According to new research in the journal Immunity, T cells have a nuclear receptor doing something very odd - but very important - to help them fight pathogens and destroy cancer cells.

T-cell gene rearrangement: This is a genetic test to show a group of cells with the same T-cell receptor, which confirms they all came from the same parent cell.

This receptor prompts the T-cells to actively destroy cancer cells, although its mechanism for recognizing tumors is not very precise, so the T-cells often attack healthy tissue as well.

It is the first T-cell receptor gene therapy to gain FDA approval. The approval was based on results from a multicenter, single-arm, open-label, clinical trial (SPEARHEAD-1, Cohort 1).

The added receptor on the T cell’s surface helps your immune system “see” specific proteins on the surface of cancer cells. In multiple myeloma cells, this is a protein called BCMA.

If you or a loved one has diffuse large B-cell lymphoma (DLBCL) that is no longer responding to treatment or came back after treatment, chimeric antigen receptor (CAR) T-cell therapy may be an option.

Study identifies proximity-based mechanism behind LAG-3 inhibition and introduces novel bispecific antibody for autoimmune ...

Archaic humans have contributed to large-scale variation in modern human T cell receptor genes. Immunity , 2023 DOI: 10.1016/j.immuni.2023.01.026 Cite This Page : ...